Financial results Q1 2023 Due to the worsened market outlook actions are taken to protect margins and manage costsv

Higher prices did not mitigate the continued
increase in variable costs.

Biomaterials: Sales were driven by stronger year-on-year prices, solid byproduct sales support and favourable currency exchange rates.

Outlook and guidance: Pricing, flexibility in product mix, inventory, capacity adjustments,
sourcing and logistics and reinforced cost control are in place.